Literature DB >> 17979988

Oral miltefosine in the treatment of post-kala-azar dermal leishmaniasis.

V Ramesh, N A Ansari, R K Jain, P Salotra.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17979988     DOI: 10.1111/j.1365-2230.2007.02547.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


× No keyword cloud information.
  4 in total

1.  Case Report: Treatment of Widespread Nodular Post kala-Azar Dermal Leishmaniasis with Extended-Dose Liposomal Amphotericin B in Bangladesh: A Series of Four Cases.

Authors:  Ariful Basher; Shomik Maruf; Proggananda Nath; Md Golam Hasnain; Muhammod Abdul Mukit; Azim Anuwarul; Fatima Aktar; Rupen Nath; Afm Akhtar Hossain; Abul Hasnat Milton; Dinesh Mondal; Abul Khair Mohammad Sumsuzzaman; Ridwanur Rahman; M A Faiz
Journal:  Am J Trop Med Hyg       Date:  2017-08-18       Impact factor: 2.345

2.  Report of the Post Kala-azar Dermal Leishmaniasis (PKDL) Consortium Meeting, New Delhi, India, 27-29 June 2012.

Authors:  Philippe Desjeux; Raj Shankar Ghosh; Pritu Dhalaria; Nathalie Strub-Wourgaft; Ed E Zijlstra
Journal:  Parasit Vectors       Date:  2013-07-02       Impact factor: 3.876

3.  Study on the safety and efficacy of miltefosine for the treatment of children and adolescents with post-kala-azar dermal leishmaniasis in Bangladesh, and an association of serum vitamin E and exposure to arsenic with post-kala-azar dermal leishmaniasis: an open clinical trial and case-control study protocol.

Authors:  D Mondal; M G Hasnain; M S Hossain; D Ghosh; P Ghosh; H Hossain; J Baker; R Nath; R Haque; G Matlashewski; S Hamano
Journal:  BMJ Open       Date:  2016-05-17       Impact factor: 2.692

4.  Clinico-epidemiological analysis of Post kala-azar dermal leishmaniasis (PKDL) cases in India over last two decades: a hospital based retrospective study.

Authors:  V Ramesh; Himanshu Kaushal; Ashwani Kumar Mishra; Ruchi Singh; Poonam Salotra
Journal:  BMC Public Health       Date:  2015-10-26       Impact factor: 3.295

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.